Garon EB, Hellmann MD, Costa EC, et al. Five-year long-term overall survival for patients with advanced NSCLC treated with pembrolizumab: Results from KEYNOTE-001. ASCO Annual Meeting 2019, abstract LBA9015.
Adjuvant anti-PD1 bij melanoom heeft impact op kwaliteit van leven
apr 2024 | Dermato-oncologie